Fusion Antibodies plc
LSE:FAB

Jigglypop Analysis For Fusion Antibodies plc 🤓

Fusion Antibodies trades at 14.2p within a 52-week band of 5.6–21p, hovering just above the mid-point and far from “deep value” territory. It’s up sharply from the lows but still 32% off the peak after a -18.6% month. The price sits near the 50-day average (14.0p) and above the 200-day (11.4p), signalling tentative support rather than conviction. Fundamentals remain early-stage: losses narrowed but revenue fell and cash tightened. The OptiMAL platform launch and NIH/NCI interest are positive, yet any extension requires approvals and is not guaranteed. Market cap c. £16m underscores micro-cap volatility. Net: this is a speculative, catalyst-driven CRO play, not a value buy. Momentum hinges on contract flow and confirmation of the NCI extension into 2026 and execution.

About Fusion Antibodies plc 👋

Fusion Antibodies plc is a contract research organization that researches, develops, and manufactures recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, Europe, North America, and worldwide. Its services include monoclonal antibody discovery and development, antibody sequencing and engineering, antibody humanization with a rational affinity maturation platform, recombinant protein expression, and stable cell line development with cGMP scale-up. The company serves pharmaceutical, biotech, veterinary, diagnostic, and life science research clients. It has a collaboration with the National Cancer Institute for the use of OptiMAL. Fusion Antibodies plc was incorporated in 2000 and is based in Belfast, United Kingdom.